Agonistic antibodies to human glucocorticoid-induced tumor necrosis factor receptor as potential stimulators of T cell immunity for the treatment of cancer and viral infections

Bibliography

• WATTS TH: TNF/TNFR family members in costimulation of T cell responses. Ann. Rev. Immunol. (2005) 23:23-68.
   PubMed Web of Science ®Google Scholar
• SO T, LEE SW, CROFT M: TNF/TNF receptor family members that positively regulate immunity. Int. J. Hematol. (2006) 83:1-11.
   PubMed Web of Science ®Google Scholar
• RILEY JL, JUNE CH: The CD28 family: a T cell rheostat for therapeutic control of T cell activation. Blood (2005) 105:13-21.
   PubMed Web of Science ®Google Scholar
• PICCIRILLO CA, SHEVACH EM: Naturally-occurring CD4+ CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. (2004) 16:81-88.
   PubMed Web of Science ®Google Scholar
• BEISSERT S, SCHWARZ A, SCHWARZ T: Regulatory T cells. J. Invest. Dermatol. (2006) 126:15-24.
   PubMed Web of Science ®Google Scholar
• LIU H, LEUNG BP: CD4+ CD25+ regulatory T cells in health and disease. Clin. Exp. Pharmacol. Physiol. (2006) 33:519-524.
   PubMed Web of Science ®Google Scholar
• WANG RF: Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin. Immunopathol. (2006) 28:17-23.
   PubMedGoogle Scholar
• ROUSE BT, SUVAS S: Regulatory cells and infectious agents: detentes cordiale and contraire. J. Immunol. (2004) 173:2211-2215.
   PubMed Web of Science ®Google Scholar
• NOCENTINI G, RICCARDI C: GITR: a multifaceted regulator of immunity belonging to the TNF receptor superfamily. Eur. J. Immunol. (2005) 35:1016-1022.
   PubMed Web of Science ®Google Scholar
• NOCENTINI G, GIUNCHI L, RONCHETTI S et al.: A new member of the TNF/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc. Natl. Acad. Sci. USA (1997) 94:6216-6221.
   PubMed Web of Science ®Google Scholar
• KWON B, YU KY, NI J et al.: Identification of a novel activation- inducible protein of the TNF receptor superfamily and its ligand. J. Biol. Chem. (1999) 274:6056-6061.
   PubMed Web of Science ®Google Scholar
• GURNEY AL, MARSTERS SA, HUANG RM et al.: Identification of a new member of the TNF family and its receptor, a human ortholog of mouse GITR. Curr. Biol. (1999) 9:215-218.
   PubMed Web of Science ®Google Scholar
• SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. (2002) 3:135-142.
   PubMed Web of Science ®Google Scholar
• MCHUGH R S, WHITTERS MJ, PICCIRILLO CA et al.: CD4+ CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 16:311-323.
   PubMed Web of Science ®Google Scholar
• LI Z, MAHESH S P, KIM BJ, BUGGAGE RR, NUSSENBLATT RB: Expression of glucocorticoid induced TNF receptor family related protein (GITR) on peripheral T cells from normal human donors and patients with non-infectious uveitis. J. Autoimmun. (2003) 21:83-92.
   PubMed Web of Science ®Google Scholar
• SCOTTO L, NAIYER AJ, GALLUZZO S et al.: Overlap between molecular markers expressed by naturally occurring CD4+ CD25+ regulatory T cells and antigen specific CD4+ CD25+ and CD8+ CD28- T suppressor cells. Hum. Immunol. (2004) 65:1297-1306.
   PubMed Web of Science ®Google Scholar
• IKEDAM, TAKESHIMA F, OHBA K et al.: Flow cytometric analysis of expression of transforming growth factor-β and glucocorticoid-induced TNF receptor on CD4+ CD25+ T cells of patients with inflammatory bowel disease. Dig. Dis. Sci. (2006) 51:178-184.
   PubMedGoogle Scholar
• AHN JS, KRISHNADAS DK, AGRAWAL B: Dendritic cells partially abrogate the regulatory activity of CD4+ CD25+ T cells present in the human peripheral blood. Int. Immunol. (2007) 19:227-237.
   PubMedGoogle Scholar
• MURIGLAN SJ, RAMIREZ-MONTAGUT T, ALPDOGAN O et al.: GITR activation induces an opposite effect on alloreactive CD4+ and CD8+ T cells in graft-versus-host disease. J. Exp. Med. (2004) 200:149-157.
   PubMed Web of Science ®Google Scholar
• TONE M, TONE Y, ADAMS E et al.: Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. USA (2003) 100:15059-15064.
   PubMed Web of Science ®Google Scholar
• KIM JD, CHOI BK, BAE JS et al.: Cloning and characterization of GITR ligand. Genes Immun. (2003) 4:564-569.
   PubMed Web of Science ®Google Scholar
• CARDONA ID, GOLEVAE, OU LS, LEUNG DY: Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. J. Allergy Clin. Immunol. (2006) 117:688-695.
   PubMed Web of Science ®Google Scholar
• NARDELLI B, ZARITSKAYA L, MCAULIFFE W et al.: Osteostat/TNF superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells. Endocrinology (2006) 147:70-78.
   PubMed Web of Science ®Google Scholar
• HANABUCHI S, WATANABE N, WANG YH et al.: Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced TNF receptor-ligand (GITRL). Blood (2006) 107:3617-3623.
   PubMed Web of Science ®Google Scholar
• JI H B, LIAO G, FAUBION WA et al.: Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J. Immunol. (2004) 172:5823-5827.
   PubMedGoogle Scholar
• ESPARZA EM, ARCH RH: Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J. Immunol. (2005) 174:7869-7874.
   PubMed Web of Science ®Google Scholar
• ESPARZA EM, LINDSTEN T, STOCKHAUSEN JM, ARCH RH: TNF receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells. J. Biol. Chem. (2006) 281:8559-8564.
   PubMedGoogle Scholar
• OBERG HH, WESCH D, LENKE J, KABELITZ D: An optimized method for the functional analysis of human regulatory T cells. Scand. J. Immunol. (2006) 64:353-360.
   PubMedGoogle Scholar
• STEPHENS GL, MCHUGH RS, WHITTERS MJ et al.: Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells. J. Immunol. (2004) 173:5008-5020.
   PubMed Web of Science ®Google Scholar
• SHEVACH EM, STEPHENS GL: The GITR-GITRL interaction: costimulation or contrasuppression of regulatory activity? Nat. Rev. Immunol. (2006) 6:613-618.
   PubMed Web of Science ®Google Scholar
• KANAMARU F, YOUNGNAK P, HASHIGUCHI M et al.: Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J. Immunol. (2004) 172:7306-7314.
   PubMed Web of Science ®Google Scholar
• RONCHETTI S, ZOLLO O, BRUSCOLI S et al.: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur. J. Immunol. (2004) 34:613-622.
   PubMed Web of Science ®Google Scholar
• KOHM AP, WILLIAMS JS, MILLER SD: Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis. J. Immunol. (2004) 172:4686-4690.
   PubMed Web of Science ®Google Scholar
• NDHLOVU LC, TAKEDA I, SUGAMURA K, ISHII N: Expanding role of T cell costimulators in regulatory T cell function: recent advances in accessory molecules expressed on both regulatory and nonregulatory T cells. Crit. Rev. Immunol. (2004) 24:251-266.
   PubMedGoogle Scholar
• KIM BJ, LI Z, FARISS RN et al.: Constitutive and cytokine-induced GITR ligand expression on human retinal pigment epithelium and photoreceptors. Invest. Ophthalmol. Vis. Sci. (2004) 45:3170-3176.
   PubMed Web of Science ®Google Scholar
• MAHESH SP, LI Z, LIU B, FARISS RN, NUSSENBLATT RB: Expression of GITR ligand abrogates immunosuppressive function of ocular tissue and differentially modulates inflammatory cytokines and chemokines. Eur. J. Immunol. (2006) 36:2128-2138.
   PubMed Web of Science ®Google Scholar
• URAUSHIHARA K, KANAI T, KO K et al.: Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. J. Immunol. (2003) 171:708-716.
   PubMed Web of Science ®Google Scholar
• PATEL M, XU D, KEWIN P et al.: Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis. Eur. J. Immunol. (2005) 35:3581-3590.
   PubMed Web of Science ®Google Scholar
• MORRIS GP, KONG YC: Interference with CD4+ CD25+ T cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced TNF receptor mAb. J. Autoimmun. (2006) 26:24-31.
   PubMedGoogle Scholar
• LEE SK, CHOI BK, KIM YH et al.: Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells. Immunology (2006) 119:479-487.
   PubMedGoogle Scholar
• SUVAS S, KIM B, SARANGI PP et al.: In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology. J. Virol. (2005) 79:11935-11942.
   PubMed Web of Science ®Google Scholar
• LA S, KIM E, KWON B: In vivo ligation of glucocorticoid-induced TNF receptor enhances the T cell immunity to herpes simplex virus type 1. Exp. Mol. Med. (2005) 37:193-198.
   PubMed Web of Science ®Google Scholar
• DITTMER U, HE H, MESSER RJ et al.: Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 20:293-303.
   PubMed Web of Science ®Google Scholar
• HE H, MESSER RJ, SAKAGUCHI S et al.: Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection. Virology (2004) 78:11641-11647.
   Google Scholar
• KO K, YAMAZAKI S, NAKAMURA K et al.: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells. J. Exp. Med. (2005) 202:885-891.
   PubMed Web of Science ®Google Scholar
• TURK MJ, GUEVARA-PATINO JA, RIZZUTO GA et al.: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. (2004) 200:771-782.
   PubMed Web of Science ®Google Scholar
• RAMIREZ-MONTAGUT T, CHOW A, HIRSCHHORN-CYMERMAN D et al.: Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. (2006) 176:6434-6442.
   PubMed Web of Science ®Google Scholar
• COHEN AD, DIAB A, PERALES MA et al.: Agonist anti-GITR antibody enhances vaccine-induced CD8+ T cell responses and tumor immunity. Cancer Res. (2006) 66:4904-4912.
   PubMed Web of Science ®Google Scholar
• HWANG WY, ALMAGRO JC, BUSS TN, TAN P, FOOTE J: Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods (2005) 36:35-42.
   PubMed Web of Science ®Google Scholar
• MORSE MA, CLAY TM, MOSCA P, LYERLY HK: Immunoregulatory T cells in cancer immunotherapy. Expert Opin. Biol. Ther. (2002) 2:827-834.
   PubMed Web of Science ®Google Scholar
• ORMANDY LA, HILLEMANN T, WEDEMEYER H et al.: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. (2005) 65:2457-2464.
   PubMed Web of Science ®Google Scholar
• LIYANAGE UK, GOEDEGEBUURE PS, MOORE TT et al.: Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J. Immunother. (2006) 29:416-424.
   PubMed Web of Science ®Google Scholar
• BAECHER-ALLAN C, ANDERSON DE: Regulatory cells and human cancer. Semin. Cancer Biol. (2006) 16:98-105.
   PubMed Web of Science ®Google Scholar
• STONE GW, BARZEE S, SNARSKY V et al.: Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J. Virol. (2006) 80:1762-1772.
   PubMed Web of Science ®Google Scholar
• NAGAI H, HORIKAWA T, HARA I et al.: In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with IL-12 gene transfer. Exp. Dermatol. (2004) 13:613-620.
   PubMed Web of Science ®Google Scholar
• EL ANDALOUSSI A, HAN Y, LESNIAK MS: Prolongation of survival following depletion of CD4+ CD25+ regulatory T cells in mice with experimental brain tumors. J. Neurosurg. (2006) 105:430-437
   PubMedGoogle Scholar
• IMAI H, SAIO M, NONAKA K et al.: Depletion of CD4+ CD25+ regulatory T cells enhances IL-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. (2007) 98:416-423.
   PubMed Web of Science ®Google Scholar
• RAMIREZ CB, MARINO IR: The role of basiliximab induction therapy in organ transplantation. Expert Opin. Biol. Ther. (2007) 7:137-148.
   PubMed Web of Science ®Google Scholar
• ISHIDA T, UEDA R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. (2006) 97:1139-1146.
   PubMed Web of Science ®Google Scholar
• QUEZADA SA, PEGGS KS, CURRAN MA, ALLISON JP: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. (2006) 116:1935-1945.
   PubMed Web of Science ®Google Scholar
• PEGGS KS, QUEZADA SA, KORMAN AJ, ALLISON JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. (2006) 8:206-213.
   Google Scholar
• SANDERSON K, SCOTLAND R, LEE P et al.: Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T lymphocyte antigen-4 mAb with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. (2005) 23:741-750.
   PubMed Web of Science ®Google Scholar
• RIBAS A, CAMACHO LH, LOPEZ-BERESTEIN G et al.: Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 mAb CP-675,206. J. Clin. Oncol. (2005) 23:8968-8977.
   PubMed Web of Science ®Google Scholar
• REUBEN JM, LEE BN, LI C et al.: Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer (2006) 106:2437-2444.
   PubMed Web of Science ®Google Scholar
• BECK KE, BLANSFIELD JA, TRAN KQ et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte-associated antigen 4. J. Clin. Oncol. (2006) 24:2283-2289.
   PubMed Web of Science ®Google Scholar
• GRAY JC, JOHNSON PW, GLENNIE MJ: Therapeutic potential of immunostimulatory monoclonal antibodies. Clin. Sci. (2006) 111:93-106.
   PubMedGoogle Scholar
• SHI W, SIEMANN DW: Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res. (2006) 26:3445-3453.
   PubMed Web of Science ®Google Scholar
• MCMILLIN DW, HEWES B, GANGADHARAN B et al.: Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. Hum. Gene Ther. (2006) 17:798-806.
   PubMedGoogle Scholar
• HARRISON JM, BERTRAM EM, RAMSHAW IA: Exploiting 4-1BB costimulation for enhancing antiviral vaccination. Viral Immunol. (2006) 19:593-601.
   PubMedGoogle Scholar
• WEINBERG AD, RIVERA MM, PRELL R et al.: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. (2000) 164:2160-2169.
   PubMed Web of Science ®Google Scholar
• SUGAMURA K, ISHII N, WEINBERG AD: Therapeutic targeting of the effector T cell costimulatory molecule OX40. Nat. Rev. Immunol. (2004) 4:420-431.
   PubMed Web of Science ®Google Scholar
• MURATA S, LADLE BH, KIM PS et al.: OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol. (2006) 176:974-983.
   PubMed Web of Science ®Google Scholar
• WEINBERG AD, THALHOFER C, MORRIS N et al.: Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J. Immunother. (2006) 29:575-585.
   PubMedGoogle Scholar
• VALZASINA B, GUIDUCCI C, DISLICH H et al.: Triggering of OX40 (CD134) on CD4+ CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood (2005) 105:2845-2851.
   PubMed Web of Science ®Google Scholar
• KOCAK E, LUTE K, CHANG X et al.: Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. (2006) 66:7276-7284.
   PubMed Web of Science ®Google Scholar
• TAYLOR MD, LEGOFF L, HARRIS A et al.: Removal of regulatory T cell activity reverses hyporesponsiveness and leads to filarial parasite clearance in vivo. J. Immunol. (2005) 174:4924-4933.
   PubMed Web of Science ®Google Scholar